Thylacine Biotherapeutics, Inc.
Biotechnology company developing lipid-conjugated peptide antivirals that target conserved viral fusion regions for prevention and treatment of respiratory viruses. Activities emphasize rapid sequence-to-candidate workflows, design and synthesis of lipopeptide candidates, preclinical evaluation in vitro and in animal models, and progression of selected candidates toward production and distribution.
Industries
N/A
Nr. of Employees
small (1-50)
Thylacine Biotherapeutics, Inc.
525 71st Street P.O. Box #415221, Miami Beach, FL 33141
Products
Lipopeptide antiviral candidates (pipeline)
Pipeline of lipid‑conjugated peptide therapeutic candidates designed to inhibit viral membrane fusion by engaging conserved fusion subdomains, aiming to treat and prevent respiratory virus infection and block transmission.
Lipopeptide antiviral candidates (pipeline)
Pipeline of lipid‑conjugated peptide therapeutic candidates designed to inhibit viral membrane fusion by engaging conserved fusion subdomains, aiming to treat and prevent respiratory virus infection and block transmission.
Services
Collaborative design, synthesis and preclinical evaluation of lipid‑conjugated peptide candidates that target conserved viral fusion regions and block membrane fusion.
Project‑based in vitro, ex vivo and in vivo potency and transmission‑prevention studies, plus ADME/DMPK and toxicology study design to support candidate advancement.
Collaborative design, synthesis and preclinical evaluation of lipid‑conjugated peptide candidates that target conserved viral fusion regions and block membrane fusion.
Project‑based in vitro, ex vivo and in vivo potency and transmission‑prevention studies, plus ADME/DMPK and toxicology study design to support candidate advancement.
Expertise Areas
- Antiviral peptide and lipopeptide therapeutics
- Fusion‑inhibition mechanisms for enveloped viruses
- Rapid sequence‑to‑candidate response for emerging pathogens
- Preclinical efficacy and transmission‑prevention studies
Key Technologies
- Sequence‑informed peptide design and bioinformatics
- Peptide synthesis and lipid‑conjugation chemistry
- Cell‑based and ex vivo antiviral assays
- ADME/DMPK assessment methods
News & Updates
Preclinical study reporting that intranasal administration of a fusion‑inhibitory lipopeptide prevented direct‑contact transmission of SARS‑CoV‑2 in ferrets.
Study on intermediates in viral entry mechanisms relevant to fusion‑inhibitory approaches.
mBio publication reporting potency of fusion‑inhibitory lipopeptides across SARS‑CoV‑2 variants.
Nature Communications article describing protection of macaques using nebulized fusion‑inhibitory peptide.
mBio article describing inhibition of coronavirus entry using a lipid‑conjugated peptide derived from a viral HR domain.
Preclinical study reporting that intranasal administration of a fusion‑inhibitory lipopeptide prevented direct‑contact transmission of SARS‑CoV‑2 in ferrets.
Study on intermediates in viral entry mechanisms relevant to fusion‑inhibitory approaches.
mBio publication reporting potency of fusion‑inhibitory lipopeptides across SARS‑CoV‑2 variants.
Nature Communications article describing protection of macaques using nebulized fusion‑inhibitory peptide.
mBio article describing inhibition of coronavirus entry using a lipid‑conjugated peptide derived from a viral HR domain.